RecruitingPhase 3NCT03925714

Impact of P53 and SIRT1 in Type 2 Diabetes

Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin

Sponsor

Sherief Abd-Elsalam

Enrollment

90 participants

Start Date

Apr 1, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how two proteins — p53 (a protective protein) and SIRT1 (an energy-regulating protein) — are involved in the early development of type 2 diabetes in people who currently have prediabetes (blood sugar that is higher than normal but not yet diabetic). **You may be eligible if...** - You have been diagnosed with prediabetes (borderline high blood sugar) - You are willing to provide samples for research **You may NOT be eligible if...** - You already have a confirmed diagnosis of type 2 diabetes - You have significant liver or kidney disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERlife style

life sryle control only

DRUGMetformin

metformin twice daily

DRUGNigetella salivata

NS twice daily

Locations(1)

Sherief Abd-Elsalam

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03925714

Related Trials

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

NCT070934761 location